Cogent bBosiences获得高达4亿美元的非稀释性融资

2025-06-11 20:11

Cogent Biosciences (NASDAQ:COGT) announced on Wednesday it has secured a debt financing facility of up to $400 million with credit funds managed by SLR Capital Partners.
Under the terms of the agreement, Cogent drew $50 million from the facility at closing. An additional $100 million is available during 2025 at Cogent’s discretion, subject to successful top-line data readouts from SUMMIT and PEAK bezuclastinib pivotal trials.
"An additional $50 million is available upon achievement of early commercial success following bezuclastinib launch. The remaining $200 million is available at mutual agreement of Cogent and SLR," said the company.
Cogent said it remains on track in July to announce top-line results from SUMMIT, a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with NonAdvSM.
COGT +0.40% premarket to $7.45.
Source: Press Release

More on Cogent Biosciences